XSHG
600671
Market cap416mUSD
Oct 09, Last price
22.92CNY
1D
0.22%
1Q
19.31%
Jan 2017
-25.61%
Name
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, a company founded in 1958 and based in Hangzhou, China, operates a multifaceted business primarily focused on the pharmaceutical sector. Through its various subsidiaries, the company specializes in both the production and distribution of medicines throughout China. Its extensive product range includes the manufacturing and sale of a diverse array of pharmaceuticals and health-related goods. These encompass various dosage forms such as tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, and soft capsules, as well as a selection of health foods. Beyond finished products, Hangzhou TianMuShan is also involved in the trade of raw materials like menthol and peppermint oil. The company also offers a comprehensive selection of traditional Chinese medicine, including prepared formulas, individual herbal pieces, and fresh herbs. Furthermore, it provides specialized medical services such as custom decoction preparation and delivery, herbal slicing and powder grinding, and traditional Chinese medicine diagnosis and treatment. In addition to its core pharmaceutical activities, the enterprise has diversified into other ventures, including software development, remote health management solutions, commercial property administration, food services, and internet information businesses.
Key people
Yulin Li
Vice Chairman of the Board · since 2012
Yining Xu
Vice Chairman of the Board · since 2013
Chengquan Yang
Vice Chairman of the Board · since 2013
Feifan Zhao
Chairman of the Board, Acting Chief Financial Officer · since 2019
Zuyue Li
General Manager · since 2018
Jian Han
Director · since 2013
Hong Cui
Independent Director · since 2012
Zhuangcheng Xu
Independent Director · since 2013
Tan Ye
Independent Director · since 2012
Ling Zhang
Independent Director · since 2013
Xudong Zhao
Independent Director · since 2012
Lixin Zheng
Independent Director · since 2013
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||